Lissencephaly Market

Market Overview:

The 7 major lissencephaly markets reached a value of USD 180.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 434.1 Million by ​2035​, exhibiting a growth rate (CAGR) of 8.36% during ​2025-2035​.

The lissencephaly market has been comprehensively analyzed in IMARC's new report titled "Lissencephaly Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Lissencephaly is a group of rare brain abnormalities in which the entire or partial surface of the brain appears smooth. It is caused by abnormal neuronal migration between the 12th and 24th weeks of gestation, resulting in a lack of development of brain folds (gyri) and grooves (sulci). It's a type of cephalic disease. Affected children exhibit significant psychomotor impairment, an abnormally small head size, failure to thrive, seizures, and muscular stiffness or hypotonia. Other signs of the condition include strange facial features, gastroesophageal reflux, trouble eating, and hand, finger, or toe deformities. The diagnostic evaluation of this condition is based on a combination of clinical observation, medical history review, and physical examination. The healthcare professional might also recommend an electroencephalogram (EEG) that can help assess brain electrical activity and may reveal abnormalities associated with lissencephaly. In some cases, magnetic resonance imaging (MRI) might be utilized for visualizing the brain's structure and confirming the presence of a smooth brain surface (agyria) or abnormally wide gyri (pachygyria).

The escalating prevalence of genetic mutations in certain genes that disrupt neuronal migration during brain development, leading to a lack of normal brain folds and grooves, is primarily driving the lissencephaly market. In addition to this, the inflating utilization of anticonvulsant medications, including vigabatrin, clobazam, phenobarbital, etc., to help manage seizures and improve quality of life while minimizing complications, is also creating a positive outlook for the market. Moreover, the widespread adoption of ventriculoperitoneal (VP) shunt technique, in which a small catheter is surgically placed into one of the brain's ventricles to drain excess cerebrospinal fluid and relieve pressure on the brain, is further bolstering the market growth. Apart from this, the rising usage of physical and occupational therapy on account of its numerous advantages, such as improved mobility, enhanced upper limb strength, and boosted independence, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene replacement technique, since it involves delivering a functional copy of a mutated gene to correct the genetic defect, is expected to drive the lissencephaly market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the lissencephaly market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lissencephaly and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lissencephaly market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the lissencephaly market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the lissencephaly market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lissencephaly marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the lissencephaly market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the lissencephaly market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the lissencephaly market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of lissencephaly across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of lissencephaly by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of lissencephaly by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with lissencephaly across the seven major markets?
• What is the size of the lissencephaly patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of lissencephaly?
• What will be the growth rate of patients across the seven major markets?

Lissencephaly: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for lissencephaly drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lissencephaly market?
• What are the key regulatory events related to the lissencephaly market?
• What is the structure of clinical trial landscape by status related to the lissencephaly market?
• What is the structure of clinical trial landscape by phase related to the lissencephaly market?
• What is the structure of clinical trial landscape by route of administration related to the lissencephaly market?